Search This Blog

Monday, November 7, 2016

Enteral Feeding: PPI and Ranitide



Cap Omeprazole 20mg
(gelatin capsule)
For swallowing difficulties:
  • Can open and contents swallowed or dispersed in slightly acidic fluid 
  • Exm: juice, sour milk, non-carbonated water

Extemporaneous Preparation:
  • 20 mg capsule contents can be dissolved in 10 mL of
  • 8.4% sodium bicarbonate to give a 2 mg_mL solution
  • stable for 14 days at RT and 45 days in
  • can be administered via nasogastric, duodenal or jejunal tube without risk of blockage or reduced efficacy.
Tab Pantoprazole 40mg
(enteric coated)
Not to be chewed or crushed
Tab Esomeprazole 20/40mg
(Gastro-resistant tablet)

The formulation is a film-coated tablet containing a compressed core of enteric coated microgranules.
  • Nexium is licensed for administration via a gastric tube.
Tab Ranitidine 150mg
Enteral Tube
  • No specific data on enteral tube administration are available for these formulations
Extemporaneous Preparation:
  • Can be prepared into a 15mg/ml syrup solution using distilled water and syrup BP
Reference
Handbook of Drug Administration via Enteral Feeding Tubes. British Pharmaceutical Nutrition Group

Friday, November 4, 2016

Switching Tiotropium Handihaler to Respimat Soft Mist


  • Tiotropium (Spiriva) is licensed as a maintenance bronchodilator treatment to relieve symptoms of COPD. 
  • Tiotropium can be delivered in two ways:
    • via the HandiHaler inhaler once daily, from a capsule containing 18 micrograms of tiotropium
    • via the soft-mist Respimat inhaler taken as two puffs once daily (2.5 micrograms of tiotropium delivered per puff)
Efficacy
  • In Japanese patients with COPD, tiotropium Respimat® 5 μg and tiotropium HandiHaler® 18 μg showed a similar profile of efficacy, safety and pharmacokinetics
  • There was a study showed that no major problem in switching from Tiotropium Handihaler to Respimat. Respimat and Handihaler showed similar effects and usability.
Adverse Events
  • risk for mortality in chronic obstructive pulmonary disease (COPD) patients being treated with tiotropium is the same whether the drug is delivered by the Respimat Soft Mist Inhaler or the HandiHaler device, a large, long-term study has found
  • In the 17,000 COPD patients followed for more than 2 years, there were no statistically significant differences in rates of mortality, myocardial infarction, or stroke between the 2 tiotropium delivery systems
  • the finding is in direct contrast to those from smaller investigations that have questioned the safety of tiotropium delivered by the Respimat device 
Technique
  • in general, both inhalers were considered to be easy to use
  • The Respimat reportedly has high levels of satisfaction in COPD patients, due to its inhalation and handling characteristics
  • The preference for the Respimat increased with continued use.
 References:
  1. https://www.gov.uk/drug-safety-update/tiotropium-delivered-via-respimat-compared-with-handihaler-no-significant-difference-in-mortality-in-tiospir-trial
  2. http://www.ncbi.nlm.nih.gov/pubmed/22691112
  3. http://reference.medscape.com/drug/spiriva-handihaler-spiriva-respimat-tiotropium-343446
  4. http://www.medscape.com/viewarticle/811257#vp_1
  5. http://www.resmedjournal.com/article/S0954-6111%2809%2900375-8/abstract
  6. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293296/ 
  7. http://bmjopen.bmj.com/content/5/5/e006619.full

Aspirin in Pregnancy

  • Indication: Preeclampsia
  • Dose: 75mg/day
Product Leaflet :
  • Aspirin should not be used in pregnancy as it may be associated with prolongation of labour and with maternal and neonatal bleeding.
Lexicomp :
  • Salicylates do cross placenta.
  • Use of aspirin close to delivery may cause premature closure of the ductus arteriosus.
  • Low dose may be used to prevent preeclampsia in women with history of early-onset preeclampsia and preterm delivery, or preeclampsia in more than 1 prior pregnancy.
  • Low dose aspirin is used to treat complications resulting from antiphospholipid syndrome in pregnancy (either primary or secondary to SLE)
  • Low dose aspirin to prevent thrombosis may also be used during the second and third trimesters in women with prosthetic valves (mechanical or bio prosthetic).
  • The use of warfarin is recommended, along with low dose aspirin, in those with mechanical valves.
  • In general, low doses during pregnancy needed for the treatment of certain medical conditions have not been shown to cause fetal harm: however, discontinuing therapy prior to delivery is recommended.
Drugs.com:
  • Aspirin has not been formally assigned to pregnancy category by the FDA. However, aspirin is considered to be in pregnancy category D by the FDA if full dose aspirin is taken in the third trimester.
  • High doses have been associated with increased perinatal mortality, intrauterine growth retardation, and teratogenic effects.
  • FDA issued a warning that it is especially important not to use aspirin during the last trimester of pregnancy unless specifically directed to do so by a physician because it may cause problems in the unborn child or complications during delivery.
  • Increased maternal bleeding can occur during delivery when aspirin is used 1 week prior to and/or during labor and delivery. Prolonged gestation and labor have been reported due to aspirin's inhibition of prostaglandin.
  • Low dose aspirin in pregnancy is safe with respect to the risks of malformation and of major impairment in development at 18 months of age
US Preventive Services:
  • Pregnant Women Who Are At High Risk for Preeclampsia: The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia.
WHO Guidelines
Antiplatelets for Prevention of Pre-eclampsia:
  • Low-dose acetylsalicylic acid (aspirin, 75 mg/day) is recommended for the prevention of pre-eclampsia in women at high risk of developing the condition. (Moderate-quality evidence, Strong recommendation)
  • Low-dose acetylsalicylic acid (aspirin, 75 mg/day) for the prevention of pre-eclampsia and its related complications should be initiated before 20 weeks of pregnancy. (Low-quality evidence, Weak recommendation)

Medication use in Glaucoma

  • Prostaglandin analogs 
    • Bimatoprost
    • Latanoprost
    • Travoprost
  • Alpha2-adrenergic agonists 
    • Nonselective
    • Epinephrine
    • Dipivefrin
    • Selective
    • Apraclonidine
    • Brimonidine
  • Beta-blocking agents* 
    • Nonselective
    • Carteolol
    • Levobunolol
    • Metipranolol
    • Timolol
    • Selective
    • Betaxolol
    • Carbonic anhydrase inhibitors 
    • Systemic, oral
    • Acetazolamide, injection or
      sustained release
    • Dichlorphenamide
    • Methazolamide
  • Topical
    • Dorzolamide
    • Brinzolamide
  • Cholinergic agonists—miotics 
    • Pilocarpine, solution or gel
    • Carbachol
  • Combination agents 
    • Timolol-dorzolamide
    • Timolol-brimonidine
Reference: 
  • www.medscape.com

Improving Tolerability : Metformin

  • Up to 30% of patients have gastrointestinal (GI) adverse effects when taking metformin
  • Generally these adverse effects are mild and transient, but about 5% of patients are unable to tolerate metformin at all
  • And almost half may not be able to tolerate the drug at a target dose of 2000 mg/day.
Initiating
  • It is generally accepted that slow dose escalation increases GI tolerability but evidence for this is lacking.
  • Start with either immediate-release (IR) or extended-release (ER) tablets.
  • If using IR, give 500 mg once daily
  • If a patient has a history of GI intolerance, consider starting with 250 mg once daily.
  • If using ER, start with 500 mg once daily
  • For even greater flexibility, metformin 100 mg/mL liquid can be used, allowing a patient to start at a lower dose and increase by smaller increments.
  • Suggest starting with single-ingredient metformin for easier titration. Once dose is established, patient can be switched to a combination product with another glucose-lowering agent if that is indicated.
Dose Titration
  • For IR or ER, increase by 500 mg per day every one to two weeks.
  • Advise patients not to break, crush, or chew the ER tablets.
  • If there is a history of GI intolerance increase more slowly, and maybe by only 250 mg at a time.
  • If GI symptoms occur, decrease the dose back to the last tolerated dose and wait at least two weeks before further increases, in a smaller increment if possible
  • It may take four to eight weeks, or longer to reach the target dose of 2000 mg/day.1 The benefit vs risk for adverse reactions does not support doses >2000 mg/day.
Tips to Improve Tolerance
  • Take with food, during or right after meals.
  • Recommend taking with the evening meal, typically the largest meal of the day
  • Dividing the daily dose may improve tolerability. Consider giving the IR product three times per day or the ER product twice daily. Some reports indicate splitting the dose has no effect on the rate of adverse effects
Patient Education
  • Let the patient know what to expect. It can be easier to tolerate some of these adverse effects if they know they’ll likely subside.
  • Persistent diarrhea will subside quickly if metformin is stopped.
  • Metformin can have an undesirable odor. Patients might even complain the odor makes them nauseous. Try a different brand or generic tablet if patients complain.
  • Let patients know that they should be patient during the titration as it will take weeks and maybe a month or two to reach the target dose.
Managing Complaints
  • Symptoms are generally transient, resolve over several months of treatment, and are reduced by slow dose titration and administration with food.
  • It is unusual for GI symptoms from metformin to begin after prolonged therapy.
  • Recommend a trial off metformin to see if symptoms resolve. You should see a resolution of symptoms within two to three days if the cause was metformin.
  • Be aware that GI symptoms that developed later in therapy may need further investigation as they could be symptoms of lactic acidosis or other serious conditions
  •  If patients cannot tolerate IR metformin at optimal doses, consider switching to a trial of ER.    
  • There have been some retrospective and observational studies that report improved GI tolerability with ER over IR tablets.  However, large, direct comparative studies are lacking.
If Can't Achieve Target Dose?
  • In most patients, there is some efficacy at a minimum dose of 500 mg/day, with a maximal effect at 2000 mg/day
  • There may be some patients who see more benefit with doses up to 2500 mg/day but there is likely to be a higher incidence of GI adverse effects.21
  • Up to 85% of the maximal effect is seen at a dose of 1500 mg/day.
  • If a patient cannot tolerate metformin IR or ER at target dose, consider adding a second agent to the maximum metformin dose they can tolerate
Adapted from
  • Improving Tolerability to Metformin. (PL Detail-Document #311202). PHARMACIST’S LETTER / PRESCRIBER’S LETTER. December 2015